Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
Three months after Biogen announced its $5.6bn buyout of rare disease specialist Apellis Pharmaceuticals, the former has decided to cull…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
Absci Corporation has secured $100m in an underwritten offering while reporting positive first-in-human (FIH) data for its lead candidate ABS-201,…
-
ŌURA and Lilly join forces to harmonise drug-wearable obesity care
ŌURA has banded together with Eli Lilly’s direct-to-consumer (DTC) telehealth platform, LillyDirect, to marry behavioural and pharmaceutical approaches to obesity…
-
AbbVie deepens immunology legacy in $10.9bn Apogee buyout
AbbVie has agreed to acquire Apogee Therapeutics for $10.9bn, potentially further fortifying its legacy in the immunology space and marking…
-
HLTH Europe 2026: enriching the patient journey with health technologies
With the pharma, biotech and medtech sectors debuting new and potentially life-changing innovations for patients at a rapid pace, many…
-
ASCO26: RLTs bring the buzz, but commercial and tolerability qualms remain
Upon its rise to notoriety spearheaded by drugs like Novartis’ Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the radiopharmaceutical field is…
-
Vedana debuts with $46m to progress migraine therapies
Vedana Therapeutics has emerged with $46m in hand from a Series A financing round, which will fund the Seattle-based biotech’s…
-
HLTH Europe 2026: obesity drugs shift the paradigm, but systemic implementation lags
With more than one billion people globally suffering from obesity, pharmaceutical approaches to treatment, such as glucagon-like peptide 1 receptor…
-
FDA oncology roundup: drugs, imaging agents and diagnostics gain approval
Over the last few days, the US Food and Drug Administration (FDA) has granted approval to several oncology products across…
-
Beren pockets $300m to take Niemann-Pick disease therapy to market
Beren Therapeutics has secured $300m in combined funding to support the potential commercial launch of its infantile-onset Niemann-Pick disease, type…